Acrivon Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Acrivon Therapeutics Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Headquarters city
Watertown
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
ACRV
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001781174
EIN
82-5125532

Board of directors

Follow this board

Chief executives

Peter Blume-Jensen · President and CEO
Dates unknown

Director election results

Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 30 other boards.

Network of Acrivon Therapeutics Inc.'s board connections Evommune Inc. Evommune Inc. Mineralys Therapeutics Inc. Mineralys Therapeutics... Werewolf Therapeutics Inc. Werewolf Therapeutics... ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... LENZ Therapeutics Inc. LENZ Therapeutics Inc. Nkarta Inc. Nkarta Inc. Parabilis Medicines Inc. Parabilis Medicines In... Derek DiRocco Derek DiRocco Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Acrivon Therapeutics Inc.
Shared director Other board Same sector +14 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$114,534
3 purchases by 3 insiders
Sold, last 12 months
$39,806
9 sales by 6 insiders
Date Insider Transaction Shares Price Value
Aug 31, 2026 Levin Michaela Officer (Chief Business Officer) Grant or award +30,000 — —
Aug 25, 2026 Peter Blume-Jensen Director, Officer (President and CEO) Open-market sale −14,036 $2.21 $30,969
Aug 18, 2026 Peter Blume-Jensen Director, Officer (President and CEO) Open-market sale −1,229 $2.01 $2,470
Aug 18, 2026 Devroe Eric Officer (Chief Operating Officer) Open-market sale −604 $2.01 $1,214
Aug 18, 2026 Gamelin Erick Officer (Chief Development Officer) Open-market sale −400 $2.01 $804
Aug 18, 2026 Miller Mary Officer (Chief Legal Officer) Open-market sale −185 $2.01 $372
Aug 18, 2026 Peterson Katharine Officer (Chief Accounting Officer) Open-market sale −101 $2.01 $203
Aug 18, 2026 Peter Blume-Jensen Director, Officer (President and CEO) Open-market sale −484 $2.01 $973
Aug 4, 2026 Levy Adam D. Officer (Chief Financial Officer) Open-market sale −1,142 $1.57 $1,793
Jul 21, 2026 Miller Mary Officer (Chief Legal Officer) Open-market sale −573 $1.76 $1,008
May 21, 2026 Kristina Masson Director, Officer (EVP - Business Operations) Shares withheld for tax −13,729 $1.79 $24,575
May 18, 2026 RA Capital Nexus Fund II, L.P. Director Grant or award +9,366 — —
May 18, 2026 Michael John Tomsicek Director Grant or award +9,366 — —
May 18, 2026 Sharon Shacham Director Grant or award +9,366 — —
May 18, 2026 Santhosh Palani Director Grant or award +9,366 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.